| Literature DB >> 31057680 |
Hian Liang Huang1,2, Aaron Kian Ti Tong1,2, Sue Ping Thang1,2, Sean Xuexian Yan1,2, Winnie Wing Chuen Lam1,2, Kelvin Siu Hoong Loke1,2, Charlene Yu Lin Tang1, Lenith Tai Jit Cheng1, Gideon Su Kai Ooi1, Han Chung Low1, Butch Maulion Magsombol1, Wei Ying Tham1,2, Charles Xian Yang Goh1,2, Colin Jingxian Tan1, Yiu Ming Khor1,2, Sumbul Zaheer1,2, Pushan Bharadwaj1,2, Wanying Xie1,2, David Chee Eng Ng1,2.
Abstract
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of 'personalised' medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.Entities:
Keywords: Lutetium; Radioiodine; Radium; Singapore; Theranostic; Yttrium
Year: 2019 PMID： 31057680 PMCID： PMC6473098 DOI： 10.1007/s13139-019-00580-3
Source DB: PubMed Journal: Nucl Med Mol Imaging ISSN： 1869-3474